{"ticker": {"uuid": "9f605b38-e6b9-47aa-872a-03c826c98f40", "symbol": "CMRX", "name": "Chimerix Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Glioblastoma Multiforme Market to Witness Transformational Growth Opportunities by 2036 \u2013 DelveInsight | AstraZeneca, DNAtrix, Chimerix, Northwest Therapeutics, Bayer, Kazia Therapeutics, Aivita Bio", "summary": "The Glioblastoma Multiforme (GBM) market is predicted to grow significantly, from approximately USD 900 million in 2025 to nearly USD 4.8 billion by 2036, driven by an increasing prevalence of the disease and advancements in therapeutic pipelines. Key companies like AstraZeneca, ", "url": "https://www.barchart.com/story/news/2142348/glioblastoma-multiforme-market-to-witness-transformational-growth-opportunities-by-2036-delveinsight-astrazeneca-dnatrix-chimerix-northwest-therapeutics-bayer-kazia-therapeutics-aivita-bio", "source_name": "Barchart.com", "published_at": "2026-05-27T04:40:55", "published_display": "27 May 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Chimerix Inc. (CMRX) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "The NASDAQ page for Chimerix Inc. (CMRX) provides current stock price information, showing it is trading at $8.54 with no change. The article notes that there are no analyst ratings or earnings information currently available for the company. It also promotes joining an options t", "url": "https://stockstotrade.com/quote/CMRX", "source_name": "StocksToTrade", "published_at": "2026-05-13T01:09:40", "published_display": "13 May 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "SEC announces settled order for insider trading charges related to Chimerix acquisition", "summary": "The SEC has announced a settled order against Weizheng Zeng for insider trading related to Jazz Pharmaceuticals' acquisition of Chimerix. Zeng, who was involved in the due diligence for the transaction at Jazz, purchased Chimerix stock based on material nonpublic information, res", "url": "https://fxnewsgroup.com/forex-news/regulatory/sec-announces-settled-order-for-insider-trading-charges-related-to-chimerix-acquisition/", "source_name": "FX News Group", "published_at": "2026-04-20T16:08:55", "published_display": "20 Apr 2026 16:08", "sentiment": "negative", "sentiment_pct": 20, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMRX Stock Price $8.54 | Chimerix, Inc. Live Quote", "summary": "This article provides an overview of Chimerix, Inc. (CMRX) stock, detailing its current price, market capitalization, and key financial metrics like P/E ratio and EPS. It highlights an AI-powered analysis with a \"B\" score, indicating moderate investment characteristics, and provi", "url": "https://meyka.com/stock/CMRXfinancials/balance-sheet/", "source_name": "Meyka", "published_at": "2026-04-02T17:09:44", "published_display": "02 Apr 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CMRX $8.54 intraday (Chimerix, Inc., NASDAQ) 12 Mar 2026: watch $6.67 support", "summary": "Chimerix Inc. (CMRX) is trading at $8.54 intraday on NASDAQ, presenting a potential oversold bounce opportunity with key support levels at the 50-day average of $6.67 and the 200-day average of $2.75. Meyka AI rates CMRX with a score of 67 (Grade B, HOLD suggestion), projecting a", "url": "https://meyka.com/blog/cmrx-854-intraday-chimerix-inc-nasdaq-12-mar-2026-watch-667-support-1203/", "source_name": "Meyka", "published_at": "2026-03-12T20:52:38", "published_display": "12 Mar 2026 20:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix Shares Approach Peak on Partner\u2019s Rosy Forecast", "summary": "Chimerix Inc. shares are nearing their 52-week high, driven by a rosy financial forecast from its Japanese partner, SymBio Pharmaceuticals. SymBio projects a dramatic 197.5% increase in revenue for the 2026 fiscal year, primarily attributed to brincidofovir (SyB V-1901), suggesti", "url": "https://www.ad-hoc-news.de/boerse/ueberblick/chimerix-shares-approach-peak-on-partner-s-rosy-forecast/68560162", "source_name": "AD HOC NEWS", "published_at": "2026-02-07T22:28:59", "published_display": "07 Feb 2026 22:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer", "summary": "Jazz Pharmaceuticals plc announced the appointment of Thomas Riga as Chief Business Officer, effective January 1, 2026. Mr. Riga brings over 25 years of commercial and operational experience, having previously served as chief operating and commercial officer at Chimerix Inc., whe", "url": "https://www.finansavisen.no/pressemeldinger/2026/01/08/e9e30418-5cc7-55b0-a54d-fbd4d8ae4ba2/jazz-pharmaceuticals-appoints-thomas-riga-as-chief-business-officer", "source_name": "Finansavisen", "published_at": "2026-01-08T22:05:00", "published_display": "08 Jan 2026 22:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch", "summary": "Immix Biopharma has appointed Michael Grabow as Chief Commercial Officer to lead the U.S. launch and commercialization of NXC-201, a therapeutic for relapsed/refractory AL Amyloidosis. Grabow previously led the Go-To-Market Strategy and Launch for MODEYSO\u00ae at Chimerix, a company ", "url": "https://www.globenewswire.com/news-release/2025/11/12/3186298/0/en/Immix-Biopharma-Appoints-Chief-Commercial-Officer-to-Drive-NXC-201-Launch.html", "source_name": "GlobeNewswire", "published_at": "2025-11-12T08:45:00", "published_display": "12 Nov 2025 08:45", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Former Chimerix CEO Andriole to lead Artios", "summary": "Michael Andriole, former CEO of Chimerix, has been appointed as the new CEO of Artios Pharma Ltd., succeeding Niall Martin. Andriole's appointment follows Chimerix's acquisition by Jazz Pharmaceuticals earlier this year. Additionally, Sam Whiting has joined Vividion Therapeutics ", "url": "https://www.biocentury.com/article/656732/former-chimerix-ceo-andriole-to-lead-artios", "source_name": "BioCentury", "published_at": "2025-08-14T12:46:00", "published_display": "14 Aug 2025 12:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix (CMRX) FDA Approvals, PDUFA Dates & Drug Alerts 2026", "summary": "This article details the FDA approval process for Chimerix's (CMRX) drug, dordaviprone, which is a treatment for recurrent H3 K27M-mutant diffuse glioma. It outlines a timeline of regulatory milestones, including the drug's FDA accelerated approval on August 6, 2025, NCCN recomme", "url": "https://www.marketbeat.com/stocks/NASDAQ/CMRX/fda-events/", "source_name": "MarketBeat", "published_at": "2025-07-09T04:39:54", "published_display": "09 Jul 2025 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Chimerix Inc. (CMRX) is Surging in 2025", "summary": "Chimerix Inc. (NASDAQ:CMRX) is experiencing a significant surge in 2025, driven primarily by the FDA's acceptance of its New Drug Application for dordaviprone with Priority Review and, more significantly, an acquisition announcement by Jazz Pharmaceuticals for $8.55 per share. Th", "url": "https://www.insidermonkey.com/blog/why-chimerix-inc-cmrx-is-surging-in-2025-1520621/", "source_name": "Insider Monkey", "published_at": "2025-04-30T05:46:00", "published_display": "30 Apr 2025 05:46", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMRX Stock Price, News & Analysis", "summary": "Chimerix (NASDAQ: CMRX) is a biopharmaceutical company focused on developing therapies for deadly diseases, particularly H3 K27M-mutant diffuse glioma with its lead program dordaviprone (ONC201). The company has submitted an NDA for dordaviprone, which has Priority Review and a P", "url": "https://www.stocktitan.net/overview/CMRX/", "source_name": "Stock Titan", "published_at": "2025-04-24T16:51:46", "published_display": "24 Apr 2025 16:51", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals Acquires Chimerix for $935M", "summary": "Jazz Pharmaceuticals has completed its acquisition of Chimerix Inc. for approximately $935 million, integrating Chimerix as a wholly owned subsidiary. This acquisition adds dordaviprone, a novel treatment in development for H3 K27M-mutant diffuse glioma, to Jazz's oncology portfo", "url": "https://www.contractpharma.com/breaking-news/jazz-pharmaceuticals-acquires-chimerix-for-935m/", "source_name": "Contract Pharma", "published_at": "2025-04-22T19:21:54", "published_display": "22 Apr 2025 19:21", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix Terminates Loan and Delists from Nasdaq", "summary": "Chimerix (CMRX) has terminated its loan agreement with Silicon Valley Bank and requested delisting from Nasdaq following a merger where it became a wholly-owned subsidiary of a parent company. Despite facing significant financial challenges like declining revenues and persistent ", "url": "https://www.tipranks.com/news/company-announcements/chimerix-terminates-loan-and-delists-from-nasdaq", "source_name": "TipRanks", "published_at": "2025-04-21T18:52:00", "published_display": "21 Apr 2025 18:52", "sentiment": "negative", "sentiment_pct": 29, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals acquires Chimerix for $935 million", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQRmE1RDhRdU9TS0E1RUhYalhvZmJ6bXVMWFllZG1tRDNLb0s3YVZsSzFaamZDSlh2aGpsb0hLWDNYRDZVTDl2X0dvcHVxaWQyOVZqczFINFB6MnNXalpkSzVZSEJQSmIwTEFqQkJjVW5OTVhMMGJySGpuNUlJV09NTUhPcUI4akRHLVVlOUQ0R21JQ2I3OWkyVXBPNzExZGFKVEVSUkdCcWJSQXBwMjVadg?oc=5", "source_name": "Investing.com", "published_at": "2025-04-21T07:00:00+00:00", "published_display": "21 Apr 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals Completes Acquisition of Chimerix", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQUWZlcUZVU0taSlozaHNUSGM5aFNpbWJ5YWd5UUZsZ1V5LVJNVld1VDAwRHpjSm9CZTlwb1NNT25lOV96amd4ZHFDOW5EVFhrbXc4YzBUODhKRkJxUzNSX2VqbTllUHBMSTh1Z2lOYXQweDM3Vm8wSERZcS1GVEEwd0RqMXhueUJaN2FsVUtaY09jMHdweXJ6Ym9kV2l1UHBmX0FWU0xuWThwWWpYTzJr?oc=5", "source_name": "PR Newswire", "published_at": "2025-04-21T07:00:00+00:00", "published_display": "21 Apr 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix engaged with 7 other biopharmas before choosing Jazz's $935M deal\u2014here's why it won", "summary": "Chimerix considered offers from seven other biopharmas before accepting Jazz Pharmaceuticals' $935 million acquisition deal. The company's board favored Jazz's all-cash offer due to its immediate value for stockholders, the bearish financial climate in biopharma, and general mark", "url": "https://www.fiercebiotech.com/biotech/chimerix-engaged-7-other-biopharmas-choosing-jazzs-935m-deal-heres-why-jazz-won", "source_name": "Fierce Biotech", "published_at": "2025-03-21T17:17:00", "published_display": "21 Mar 2025 17:17", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix Inc. (CMRX) reports earnings", "summary": "Chimerix Inc. (CMRX) reported a net loss of $88.4 million for the fiscal year ended December 31, 2024, with total revenues of $0.2 million. The company is focusing on its lead product candidate, dordaviprone, and recently entered into a merger agreement with Jazz Pharmaceuticals,", "url": "https://qz.com/chimerix-inc-cmrx-reports-earnings-1851771509", "source_name": "qz.com", "published_at": "2025-03-21T00:00:00", "published_display": "21 Mar 2025 00:00", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Chimerix, Inc. (CMRX) Soared Last Week", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPWU5kS19NeThBUUgwRnNGMnEzU25yaTdJWmI2SElzaTlDT2hnOTZhX3NfZkhlcU5Kd2pocGdaRjhSMTlraWp3Q1RQNm9kYTJCOGpEUlFpVjFJcGZYVXdEWjhVZFVJeXdzNzNGR1oya3dVS08wMjhqTjJhQXBiSXhsaEF0eU42SDB1eUHSAZIBQVVfeXFMUDFCSkhGd2YwdTM4Q0hBaEp5TG4xblU2a1NITERTNjRFdTY0d3JsVlUxWUVLWjYybmRVczVHS1o5OF9HNW1RcG9XSHQ1czFVV2NSaTBCLUszZ0QyQkhZTUxVcHR2SnNtMmFUZS1CR0hwUnVhQXo3d01WWVo5R0QzWHFDeGRZYmdFcjcxNEJyR2N3Z1E?oc=5", "source_name": "Insider Monkey", "published_at": "2025-03-09T08:00:00+00:00", "published_display": "09 Mar 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "First-in-Class Brain Cancer Drug Strikes a Chord With Jazz Pharma to the Tune of a $935M M&A Deal", "summary": "Jazz Pharmaceuticals is set to acquire Chimerix for $935 million, primarily for dordaviprone, a first-in-class brain cancer drug targeting H3 K27M-mutant diffuse glioma. This acquisition aims to address a significant unmet medical need for a rare and aggressive form of brain canc", "url": "https://medcitynews.com/2025/03/jazz-pharmaceuticals-chimerix-acquisition-brain-cancer-glioma-dordaviprone-cmrx/", "source_name": "MedCity News", "published_at": "2025-03-06T20:40:19", "published_display": "06 Mar 2025 20:40", "sentiment": "positive", "sentiment_pct": 91, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix turns $39m into $935m | ApexOnco - Clinical Trials news and analysis", "summary": "Jazz Pharmaceuticals acquired Chimerix for $935 million, primarily for its lead asset dordaviprone, which Chimerix had acquired through Oncoceutics for just $78 million. This acquisition represents a success for Chimerix, particularly given the struggles of its previous lead proj", "url": "https://www.oncologypipeline.com/apexonco/chimerix-turns-39m-935m", "source_name": "Oncology Pipeline", "published_at": "2025-03-05T22:09:07", "published_display": "05 Mar 2025 22:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of", "summary": "Brodsky & Smith is reminding investors about ongoing investigations into the acquisitions of Chimerix, Inc. (CMRX), Siyata Mobile Inc. (SYTA), Bridge Investment Group Holdings Inc. (BRDG), and Intevac, Inc. (IVAC). The law firm is investigating whether the boards of these compani", "url": "https://www.globenewswire.com/news-release/2025/03/05/3037654/0/en/BRODSKY-SMITH-SHAREHOLDER-UPDATE-Notifying-Investors-of-the-Following-Investigations-Chimerix-Inc-Nasdaq-CMRX-Siyata-Mobile-Inc-Nasdaq-SYTA-Bridge-Investment-Group-Holdings-Inc-NYS.html", "source_name": "GlobeNewswire", "published_at": "2025-03-05T12:27:00", "published_display": "05 Mar 2025 12:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPbnpJMGdqTmRsSFRJTWxXcHNLaU5zcmJENTVwMjhpNU1jOHhfbVN4VmN0UnpCY2U4U3ptTHJfUzZjYktMZElWRGpfRkV1V0hwbC1YbUp2NmRMNGFSOUgzVzhjWUswd29OV18wYy1TTTFMN1NYaVpzd2tTR1c3aVJaNGhKVW91c242c1hMWEN6WVBqVEJRdkVOSmxqWEhTOVh3NWJYNUxpVC1qWnF6Q1B1VnhOTkJ4NDV1ZjVRdUUtdVJKbkRsSTlhYzk5OHpwaG5rTnc?oc=5", "source_name": "PR Newswire", "published_at": "2025-03-05T08:00:00+00:00", "published_display": "05 Mar 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz To Buy Chimerix For $935 Mln To Boost Oncology Portfolio, CMRX Up In Pre-Market", "summary": "Jazz Pharmaceuticals Plc. announced a deal to acquire Chimerix Inc. for approximately $935 million, or $8.55 per share in cash, representing a 72 percent premium. The acquisition is expected to close in Q2 2025 and aims to boost Jazz's oncology portfolio with Chimerix's lead asse", "url": "https://www.nasdaq.com/articles/jazz-buy-chimerix-935-mln-boost-oncology-portfolio-cmrx-pre-market", "source_name": "Nasdaq", "published_at": "2025-03-05T07:53:00", "published_display": "05 Mar 2025 07:53", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharma Pays 72% Premium for Chimerix: Is This Rare Disease Drug Worth $935M?", "summary": "Jazz Pharmaceuticals announced the acquisition of Chimerix for approximately $935 million, representing a 72% premium, to gain control of dordaviprone, a promising drug for rare brain tumors. This acquisition is expected to close in Q2 2025 and positions Jazz for a potential near", "url": "https://www.stocktitan.net/news/CMRX/jazz-pharmaceuticals-to-acquire-chimerix-further-diversifying-c0jirusuxd8y.html", "source_name": "Stock Titan", "published_at": "2025-03-05T07:00:00", "published_display": "05 Mar 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals to acquire Chimerix and its experimental brain cancer drug", "summary": "Jazz Pharmaceuticals announced its intent to acquire Chimerix for nearly $1 billion, primarily for Chimerix's experimental brain cancer drug, dordaviprone. This drug is aimed at diffuse midline glioma (DMG), a devastating brain tumor, particularly in children and young adults, wh", "url": "https://www.statnews.com/2025/03/05/jazz-chimerix-acquisition-dordaviprone-brain-cancer/", "source_name": "STAT", "published_at": "2025-03-05T01:40:09", "published_display": "05 Mar 2025 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharma aims to boost cancer drug pipeline with $935 million buyout - San Francisco Business Times", "summary": "Jazz Pharmaceuticals plans to acquire cancer-focused Chimerix for $935 million to enhance its oncology drug pipeline. The deal is expected to close in the second quarter. Bruce Cozadd is the chairman and CEO of Jazz Pharmaceuticals plc.", "url": "https://www.bizjournals.com/sanfrancisco/news/2025/03/05/brain-cancer-jazz-pharmaceuticals-chimerix.html", "source_name": "The Business Journals", "published_at": "2025-03-05T00:00:00", "published_display": "05 Mar 2025 00:00", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix stock rises on FDA priority review for dordaviprone By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOak1mcE5EMGhIdldBcGMzX3BGM25LS24yd2NZaGNYd2NsLVZfZTBNZmFwTzNMSkdSYTVQSjlGNmk2N3VZUXJRb08yeWR3YmI5bmdyMEIzNFNhY0hwbE1xUUhmVnU4dUI2QjlQSmJvaFVJVElETXQ0SjhRU3dPTUFFVDRqZlZ5M3VaV29TMWdfOERubWZrOWZJSEcxZWJTOEgtdmRWSlZGbUNPaFFVaE9qTS1kVFQxUmMwbzhHZVdR?oc=5", "source_name": "Investing.com UK", "published_at": "2025-02-18T08:00:00+00:00", "published_display": "18 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix VP of finance sells $1,359 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOWWVPMXlIMWhlc2NJcDlOMWxtUGtRVExZMEhuWWx2T21jSXZNb3JfRExvTGY0bS1hUktxLWtTcUpKdzJRR3FzcEhYMUxnV1JsajI0UFZCUzNSMldUMFcyeTNiT2EwU2xadXhVVk1laEJLMDJvb1J3WG9ubDhnQ2luTHZCbkpSNHVQaE0tNGZQeHFmaDlhTDNJV0JPTHY1anJXQkhzYV9EbVJ5XzQ?oc=5", "source_name": "Investing.com", "published_at": "2025-02-14T08:00:00+00:00", "published_display": "14 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix (CMRX) Stock News & Updates", "summary": "This page provides news and updates on Chimerix (CMRX) stock, a biopharmaceutical company focused on oncology drug development, particularly dordaviprone (ONC201) for H3 K27M-mutant glioma. Key news includes its acquisition by Jazz Pharmaceuticals in April 2025, FDA priority revi", "url": "https://www.stocktitan.net/news/CMRX/", "source_name": "Stock Titan", "published_at": "2025-01-13T01:40:09", "published_display": "13 Jan 2025 01:40", "sentiment": "positive", "sentiment_pct": 79, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix Submits New Drug Application to FDA Seeking Accelerated Approval for Dordaviprone in Recurrent H3 K27M-Mutant Diffuse Glioma", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxPZzBBLTA0elJzcjdmSXNiU1Jwd2VYZWtBRjhrMFpiQ2VNeVJPbHNMMVpHckZyazBObGtzc1RPeWpvdlpRRTJ3TmVRTDQwdjF4UURDMkI3bmFEelNaYkZKWHFHeGo3Ty1JS2FUbjZ6WlRCX3k4QVVUOG9GUFVhV3Jxa05xZl92SXFYY25OdnBoaUxsQjlHWVNWZ01WVnRlZkNPV0ZicDNwU05WT2hjVURRckpERFdlSWxybU9WLVRybWVRQkkwd20tLWcydFBmdmlLX01OclVWY2xNb1ZpR3pMLVlGLU9ocllXcUtFZjczVHljTEFRR3B2dFdR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2024-12-30T08:00:00+00:00", "published_display": "30 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix Inc (CMRX) Quarterly 10-Q Report", "summary": "Chimerix Inc. (CMRX) filed its 10-Q report for the quarter ended September 30, 2024, reporting a net loss of $22.88 million, an improvement from the previous year. Revenue increased to $26,000, primarily due to contract and grant revenue, while R&D expenses rose due to the ACTION", "url": "https://qz.com/chimerix-inc-cmrx-quarterly-10-q-report-1851692369", "source_name": "qz.com", "published_at": "2024-11-07T00:00:00", "published_display": "07 Nov 2024 00:00", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix: Q3 Earnings Snapshot", "summary": "Chimerix Inc. reported a Q3 loss of $24 million, resulting in a loss of 27 cents per share, which missed Wall Street expectations of a 22-cent loss per share. The biopharmaceutical company recorded a revenue of $11,000 for the period.", "url": "https://qz.com/chimerix-q3-earnings-snapshot-1850984379", "source_name": "Quartz", "published_at": "2023-12-31T23:59:59", "published_display": "31 Dec 2023 23:59", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023", "summary": "Chimerix announced it will host a live conference call and audio webcast on Thursday, November 2, 2023, at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2023. The biopharmaceutical company will also provide a business overview during the call.", "url": "https://www.stocktitan.net/news/CMRX/chimerix-to-report-third-quarter-2023-financial-results-and-provide-pqu0w0uwvvv4.html", "source_name": "Stock Titan", "published_at": "2023-10-26T07:00:00", "published_display": "26 Oct 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix (CMRX) Dividend History, Date, and Yield", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVEFVX3lxTE81MHBsR2JZWDAwTng5U1VCUTM0eXRHdnJHNVlvb2xLZlhNWXJhZUxGUlBydk9HbXZPNE9oUVIxeUt6N2ZtVUotWTVhZkxRR1dxVVVjTA?oc=5", "source_name": "CoinCodex", "published_at": "2023-08-09T12:16:10+00:00", "published_display": "09 Aug 2023 12:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix (CMRX) Stock Live Price, Chart & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTFBlMFhhQ2FYUl85ZjBmMFpVWGVuMVVHTHdncjZLdnRWZ2xDWFVzMHBtdlJ4M2lPZlhsMjNRWnFtQVpVbndzd1dhYw?oc=5", "source_name": "CoinCodex", "published_at": "2021-03-20T04:46:14+00:00", "published_display": "20 Mar 2021 04:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix (CMRX) Stock Forecast & Price Prediction 2026\u20132030", "summary": "", "url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTE1KTzNrVnVMb3Awc1BVNGk2OExicEJ0UU42cWVXOGluUzVkbDZzRGI3YVl4Q2Rrak0xdVhEVlU2bkN6WTk2eHN6bGF4bUlFMW1CcEtpaGhvU25Ec0Z4Smxn?oc=5", "source_name": "CoinCodex", "published_at": "2021-03-15T10:16:22+00:00", "published_display": "15 Mar 2021 10:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Glioblastoma Multiforme Market to Witness Transformational Growth Opportunities by 2036 \u2013 DelveInsight | AstraZeneca, DNAtrix, Chimerix, Northwest Therapeutics, Bayer, Kazia Therapeutics, Aivita Bio", "summary": "The Glioblastoma Multiforme (GBM) market is predicted to grow significantly, from approximately USD 900 million in 2025 to nearly USD 4.8 billion by 2036, driven by an increasing prevalence of the disease and advancements in therapeutic pipelines. Key companies like AstraZeneca, ", "url": "https://www.barchart.com/story/news/2142348/glioblastoma-multiforme-market-to-witness-transformational-growth-opportunities-by-2036-delveinsight-astrazeneca-dnatrix-chimerix-northwest-therapeutics-bayer-kazia-therapeutics-aivita-bio", "source_name": "Barchart.com", "published_at": "2026-05-27T04:40:55", "published_display": "27 May 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix Inc. (CMRX) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "The NASDAQ page for Chimerix Inc. (CMRX) provides current stock price information, showing it is trading at $8.54 with no change. The article notes that there are no analyst ratings or earnings information currently available for the company. It also promotes joining an options t", "url": "https://stockstotrade.com/quote/CMRX", "source_name": "StocksToTrade", "published_at": "2026-05-13T01:09:40", "published_display": "13 May 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SEC announces settled order for insider trading charges related to Chimerix acquisition", "summary": "The SEC has announced a settled order against Weizheng Zeng for insider trading related to Jazz Pharmaceuticals' acquisition of Chimerix. Zeng, who was involved in the due diligence for the transaction at Jazz, purchased Chimerix stock based on material nonpublic information, res", "url": "https://fxnewsgroup.com/forex-news/regulatory/sec-announces-settled-order-for-insider-trading-charges-related-to-chimerix-acquisition/", "source_name": "FX News Group", "published_at": "2026-04-20T16:08:55", "published_display": "20 Apr 2026 16:08", "sentiment": "negative", "sentiment_pct": 20, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMRX Stock Price $8.54 | Chimerix, Inc. Live Quote", "summary": "This article provides an overview of Chimerix, Inc. (CMRX) stock, detailing its current price, market capitalization, and key financial metrics like P/E ratio and EPS. It highlights an AI-powered analysis with a \"B\" score, indicating moderate investment characteristics, and provi", "url": "https://meyka.com/stock/CMRXfinancials/balance-sheet/", "source_name": "Meyka", "published_at": "2026-04-02T17:09:44", "published_display": "02 Apr 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMRX $8.54 intraday (Chimerix, Inc., NASDAQ) 12 Mar 2026: watch $6.67 support", "summary": "Chimerix Inc. (CMRX) is trading at $8.54 intraday on NASDAQ, presenting a potential oversold bounce opportunity with key support levels at the 50-day average of $6.67 and the 200-day average of $2.75. Meyka AI rates CMRX with a score of 67 (Grade B, HOLD suggestion), projecting a", "url": "https://meyka.com/blog/cmrx-854-intraday-chimerix-inc-nasdaq-12-mar-2026-watch-667-support-1203/", "source_name": "Meyka", "published_at": "2026-03-12T20:52:38", "published_display": "12 Mar 2026 20:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix Shares Approach Peak on Partner\u2019s Rosy Forecast", "summary": "Chimerix Inc. shares are nearing their 52-week high, driven by a rosy financial forecast from its Japanese partner, SymBio Pharmaceuticals. SymBio projects a dramatic 197.5% increase in revenue for the 2026 fiscal year, primarily attributed to brincidofovir (SyB V-1901), suggesti", "url": "https://www.ad-hoc-news.de/boerse/ueberblick/chimerix-shares-approach-peak-on-partner-s-rosy-forecast/68560162", "source_name": "AD HOC NEWS", "published_at": "2026-02-07T22:28:59", "published_display": "07 Feb 2026 22:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer", "summary": "Jazz Pharmaceuticals plc announced the appointment of Thomas Riga as Chief Business Officer, effective January 1, 2026. Mr. Riga brings over 25 years of commercial and operational experience, having previously served as chief operating and commercial officer at Chimerix Inc., whe", "url": "https://www.finansavisen.no/pressemeldinger/2026/01/08/e9e30418-5cc7-55b0-a54d-fbd4d8ae4ba2/jazz-pharmaceuticals-appoints-thomas-riga-as-chief-business-officer", "source_name": "Finansavisen", "published_at": "2026-01-08T22:05:00", "published_display": "08 Jan 2026 22:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch", "summary": "Immix Biopharma has appointed Michael Grabow as Chief Commercial Officer to lead the U.S. launch and commercialization of NXC-201, a therapeutic for relapsed/refractory AL Amyloidosis. Grabow previously led the Go-To-Market Strategy and Launch for MODEYSO\u00ae at Chimerix, a company ", "url": "https://www.globenewswire.com/news-release/2025/11/12/3186298/0/en/Immix-Biopharma-Appoints-Chief-Commercial-Officer-to-Drive-NXC-201-Launch.html", "source_name": "GlobeNewswire", "published_at": "2025-11-12T08:45:00", "published_display": "12 Nov 2025 08:45", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Former Chimerix CEO Andriole to lead Artios", "summary": "Michael Andriole, former CEO of Chimerix, has been appointed as the new CEO of Artios Pharma Ltd., succeeding Niall Martin. Andriole's appointment follows Chimerix's acquisition by Jazz Pharmaceuticals earlier this year. Additionally, Sam Whiting has joined Vividion Therapeutics ", "url": "https://www.biocentury.com/article/656732/former-chimerix-ceo-andriole-to-lead-artios", "source_name": "BioCentury", "published_at": "2025-08-14T12:46:00", "published_display": "14 Aug 2025 12:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix (CMRX) FDA Approvals, PDUFA Dates & Drug Alerts 2026", "summary": "This article details the FDA approval process for Chimerix's (CMRX) drug, dordaviprone, which is a treatment for recurrent H3 K27M-mutant diffuse glioma. It outlines a timeline of regulatory milestones, including the drug's FDA accelerated approval on August 6, 2025, NCCN recomme", "url": "https://www.marketbeat.com/stocks/NASDAQ/CMRX/fda-events/", "source_name": "MarketBeat", "published_at": "2025-07-09T04:39:54", "published_display": "09 Jul 2025 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Chimerix Inc. (CMRX) is Surging in 2025", "summary": "Chimerix Inc. (NASDAQ:CMRX) is experiencing a significant surge in 2025, driven primarily by the FDA's acceptance of its New Drug Application for dordaviprone with Priority Review and, more significantly, an acquisition announcement by Jazz Pharmaceuticals for $8.55 per share. Th", "url": "https://www.insidermonkey.com/blog/why-chimerix-inc-cmrx-is-surging-in-2025-1520621/", "source_name": "Insider Monkey", "published_at": "2025-04-30T05:46:00", "published_display": "30 Apr 2025 05:46", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CMRX Stock Price, News & Analysis", "summary": "Chimerix (NASDAQ: CMRX) is a biopharmaceutical company focused on developing therapies for deadly diseases, particularly H3 K27M-mutant diffuse glioma with its lead program dordaviprone (ONC201). The company has submitted an NDA for dordaviprone, which has Priority Review and a P", "url": "https://www.stocktitan.net/overview/CMRX/", "source_name": "Stock Titan", "published_at": "2025-04-24T16:51:46", "published_display": "24 Apr 2025 16:51", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals Acquires Chimerix for $935M", "summary": "Jazz Pharmaceuticals has completed its acquisition of Chimerix Inc. for approximately $935 million, integrating Chimerix as a wholly owned subsidiary. This acquisition adds dordaviprone, a novel treatment in development for H3 K27M-mutant diffuse glioma, to Jazz's oncology portfo", "url": "https://www.contractpharma.com/breaking-news/jazz-pharmaceuticals-acquires-chimerix-for-935m/", "source_name": "Contract Pharma", "published_at": "2025-04-22T19:21:54", "published_display": "22 Apr 2025 19:21", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix Terminates Loan and Delists from Nasdaq", "summary": "Chimerix (CMRX) has terminated its loan agreement with Silicon Valley Bank and requested delisting from Nasdaq following a merger where it became a wholly-owned subsidiary of a parent company. Despite facing significant financial challenges like declining revenues and persistent ", "url": "https://www.tipranks.com/news/company-announcements/chimerix-terminates-loan-and-delists-from-nasdaq", "source_name": "TipRanks", "published_at": "2025-04-21T18:52:00", "published_display": "21 Apr 2025 18:52", "sentiment": "negative", "sentiment_pct": 29, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals acquires Chimerix for $935 million", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQRmE1RDhRdU9TS0E1RUhYalhvZmJ6bXVMWFllZG1tRDNLb0s3YVZsSzFaamZDSlh2aGpsb0hLWDNYRDZVTDl2X0dvcHVxaWQyOVZqczFINFB6MnNXalpkSzVZSEJQSmIwTEFqQkJjVW5OTVhMMGJySGpuNUlJV09NTUhPcUI4akRHLVVlOUQ0R21JQ2I3OWkyVXBPNzExZGFKVEVSUkdCcWJSQXBwMjVadg?oc=5", "source_name": "Investing.com", "published_at": "2025-04-21T07:00:00+00:00", "published_display": "21 Apr 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals Completes Acquisition of Chimerix", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQUWZlcUZVU0taSlozaHNUSGM5aFNpbWJ5YWd5UUZsZ1V5LVJNVld1VDAwRHpjSm9CZTlwb1NNT25lOV96amd4ZHFDOW5EVFhrbXc4YzBUODhKRkJxUzNSX2VqbTllUHBMSTh1Z2lOYXQweDM3Vm8wSERZcS1GVEEwd0RqMXhueUJaN2FsVUtaY09jMHdweXJ6Ym9kV2l1UHBmX0FWU0xuWThwWWpYTzJr?oc=5", "source_name": "PR Newswire", "published_at": "2025-04-21T07:00:00+00:00", "published_display": "21 Apr 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix engaged with 7 other biopharmas before choosing Jazz's $935M deal\u2014here's why it won", "summary": "Chimerix considered offers from seven other biopharmas before accepting Jazz Pharmaceuticals' $935 million acquisition deal. The company's board favored Jazz's all-cash offer due to its immediate value for stockholders, the bearish financial climate in biopharma, and general mark", "url": "https://www.fiercebiotech.com/biotech/chimerix-engaged-7-other-biopharmas-choosing-jazzs-935m-deal-heres-why-jazz-won", "source_name": "Fierce Biotech", "published_at": "2025-03-21T17:17:00", "published_display": "21 Mar 2025 17:17", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix Inc. (CMRX) reports earnings", "summary": "Chimerix Inc. (CMRX) reported a net loss of $88.4 million for the fiscal year ended December 31, 2024, with total revenues of $0.2 million. The company is focusing on its lead product candidate, dordaviprone, and recently entered into a merger agreement with Jazz Pharmaceuticals,", "url": "https://qz.com/chimerix-inc-cmrx-reports-earnings-1851771509", "source_name": "qz.com", "published_at": "2025-03-21T00:00:00", "published_display": "21 Mar 2025 00:00", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Chimerix, Inc. (CMRX) Soared Last Week", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPWU5kS19NeThBUUgwRnNGMnEzU25yaTdJWmI2SElzaTlDT2hnOTZhX3NfZkhlcU5Kd2pocGdaRjhSMTlraWp3Q1RQNm9kYTJCOGpEUlFpVjFJcGZYVXdEWjhVZFVJeXdzNzNGR1oya3dVS08wMjhqTjJhQXBiSXhsaEF0eU42SDB1eUHSAZIBQVVfeXFMUDFCSkhGd2YwdTM4Q0hBaEp5TG4xblU2a1NITERTNjRFdTY0d3JsVlUxWUVLWjYybmRVczVHS1o5OF9HNW1RcG9XSHQ1czFVV2NSaTBCLUszZ0QyQkhZTUxVcHR2SnNtMmFUZS1CR0hwUnVhQXo3d01WWVo5R0QzWHFDeGRZYmdFcjcxNEJyR2N3Z1E?oc=5", "source_name": "Insider Monkey", "published_at": "2025-03-09T08:00:00+00:00", "published_display": "09 Mar 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "First-in-Class Brain Cancer Drug Strikes a Chord With Jazz Pharma to the Tune of a $935M M&A Deal", "summary": "Jazz Pharmaceuticals is set to acquire Chimerix for $935 million, primarily for dordaviprone, a first-in-class brain cancer drug targeting H3 K27M-mutant diffuse glioma. This acquisition aims to address a significant unmet medical need for a rare and aggressive form of brain canc", "url": "https://medcitynews.com/2025/03/jazz-pharmaceuticals-chimerix-acquisition-brain-cancer-glioma-dordaviprone-cmrx/", "source_name": "MedCity News", "published_at": "2025-03-06T20:40:19", "published_display": "06 Mar 2025 20:40", "sentiment": "positive", "sentiment_pct": 91, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix turns $39m into $935m | ApexOnco - Clinical Trials news and analysis", "summary": "Jazz Pharmaceuticals acquired Chimerix for $935 million, primarily for its lead asset dordaviprone, which Chimerix had acquired through Oncoceutics for just $78 million. This acquisition represents a success for Chimerix, particularly given the struggles of its previous lead proj", "url": "https://www.oncologypipeline.com/apexonco/chimerix-turns-39m-935m", "source_name": "Oncology Pipeline", "published_at": "2025-03-05T22:09:07", "published_display": "05 Mar 2025 22:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of", "summary": "Brodsky & Smith is reminding investors about ongoing investigations into the acquisitions of Chimerix, Inc. (CMRX), Siyata Mobile Inc. (SYTA), Bridge Investment Group Holdings Inc. (BRDG), and Intevac, Inc. (IVAC). The law firm is investigating whether the boards of these compani", "url": "https://www.globenewswire.com/news-release/2025/03/05/3037654/0/en/BRODSKY-SMITH-SHAREHOLDER-UPDATE-Notifying-Investors-of-the-Following-Investigations-Chimerix-Inc-Nasdaq-CMRX-Siyata-Mobile-Inc-Nasdaq-SYTA-Bridge-Investment-Group-Holdings-Inc-NYS.html", "source_name": "GlobeNewswire", "published_at": "2025-03-05T12:27:00", "published_display": "05 Mar 2025 12:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPbnpJMGdqTmRsSFRJTWxXcHNLaU5zcmJENTVwMjhpNU1jOHhfbVN4VmN0UnpCY2U4U3ptTHJfUzZjYktMZElWRGpfRkV1V0hwbC1YbUp2NmRMNGFSOUgzVzhjWUswd29OV18wYy1TTTFMN1NYaVpzd2tTR1c3aVJaNGhKVW91c242c1hMWEN6WVBqVEJRdkVOSmxqWEhTOVh3NWJYNUxpVC1qWnF6Q1B1VnhOTkJ4NDV1ZjVRdUUtdVJKbkRsSTlhYzk5OHpwaG5rTnc?oc=5", "source_name": "PR Newswire", "published_at": "2025-03-05T08:00:00+00:00", "published_display": "05 Mar 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz To Buy Chimerix For $935 Mln To Boost Oncology Portfolio, CMRX Up In Pre-Market", "summary": "Jazz Pharmaceuticals Plc. announced a deal to acquire Chimerix Inc. for approximately $935 million, or $8.55 per share in cash, representing a 72 percent premium. The acquisition is expected to close in Q2 2025 and aims to boost Jazz's oncology portfolio with Chimerix's lead asse", "url": "https://www.nasdaq.com/articles/jazz-buy-chimerix-935-mln-boost-oncology-portfolio-cmrx-pre-market", "source_name": "Nasdaq", "published_at": "2025-03-05T07:53:00", "published_display": "05 Mar 2025 07:53", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharma Pays 72% Premium for Chimerix: Is This Rare Disease Drug Worth $935M?", "summary": "Jazz Pharmaceuticals announced the acquisition of Chimerix for approximately $935 million, representing a 72% premium, to gain control of dordaviprone, a promising drug for rare brain tumors. This acquisition is expected to close in Q2 2025 and positions Jazz for a potential near", "url": "https://www.stocktitan.net/news/CMRX/jazz-pharmaceuticals-to-acquire-chimerix-further-diversifying-c0jirusuxd8y.html", "source_name": "Stock Titan", "published_at": "2025-03-05T07:00:00", "published_display": "05 Mar 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharmaceuticals to acquire Chimerix and its experimental brain cancer drug", "summary": "Jazz Pharmaceuticals announced its intent to acquire Chimerix for nearly $1 billion, primarily for Chimerix's experimental brain cancer drug, dordaviprone. This drug is aimed at diffuse midline glioma (DMG), a devastating brain tumor, particularly in children and young adults, wh", "url": "https://www.statnews.com/2025/03/05/jazz-chimerix-acquisition-dordaviprone-brain-cancer/", "source_name": "STAT", "published_at": "2025-03-05T01:40:09", "published_display": "05 Mar 2025 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jazz Pharma aims to boost cancer drug pipeline with $935 million buyout - San Francisco Business Times", "summary": "Jazz Pharmaceuticals plans to acquire cancer-focused Chimerix for $935 million to enhance its oncology drug pipeline. The deal is expected to close in the second quarter. Bruce Cozadd is the chairman and CEO of Jazz Pharmaceuticals plc.", "url": "https://www.bizjournals.com/sanfrancisco/news/2025/03/05/brain-cancer-jazz-pharmaceuticals-chimerix.html", "source_name": "The Business Journals", "published_at": "2025-03-05T00:00:00", "published_display": "05 Mar 2025 00:00", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix stock rises on FDA priority review for dordaviprone By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOak1mcE5EMGhIdldBcGMzX3BGM25LS24yd2NZaGNYd2NsLVZfZTBNZmFwTzNMSkdSYTVQSjlGNmk2N3VZUXJRb08yeWR3YmI5bmdyMEIzNFNhY0hwbE1xUUhmVnU4dUI2QjlQSmJvaFVJVElETXQ0SjhRU3dPTUFFVDRqZlZ5M3VaV29TMWdfOERubWZrOWZJSEcxZWJTOEgtdmRWSlZGbUNPaFFVaE9qTS1kVFQxUmMwbzhHZVdR?oc=5", "source_name": "Investing.com UK", "published_at": "2025-02-18T08:00:00+00:00", "published_display": "18 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix VP of finance sells $1,359 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOWWVPMXlIMWhlc2NJcDlOMWxtUGtRVExZMEhuWWx2T21jSXZNb3JfRExvTGY0bS1hUktxLWtTcUpKdzJRR3FzcEhYMUxnV1JsajI0UFZCUzNSMldUMFcyeTNiT2EwU2xadXhVVk1laEJLMDJvb1J3WG9ubDhnQ2luTHZCbkpSNHVQaE0tNGZQeHFmaDlhTDNJV0JPTHY1anJXQkhzYV9EbVJ5XzQ?oc=5", "source_name": "Investing.com", "published_at": "2025-02-14T08:00:00+00:00", "published_display": "14 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix (CMRX) Stock News & Updates", "summary": "This page provides news and updates on Chimerix (CMRX) stock, a biopharmaceutical company focused on oncology drug development, particularly dordaviprone (ONC201) for H3 K27M-mutant glioma. Key news includes its acquisition by Jazz Pharmaceuticals in April 2025, FDA priority revi", "url": "https://www.stocktitan.net/news/CMRX/", "source_name": "Stock Titan", "published_at": "2025-01-13T01:40:09", "published_display": "13 Jan 2025 01:40", "sentiment": "positive", "sentiment_pct": 79, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix Submits New Drug Application to FDA Seeking Accelerated Approval for Dordaviprone in Recurrent H3 K27M-Mutant Diffuse Glioma", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxPZzBBLTA0elJzcjdmSXNiU1Jwd2VYZWtBRjhrMFpiQ2VNeVJPbHNMMVpHckZyazBObGtzc1RPeWpvdlpRRTJ3TmVRTDQwdjF4UURDMkI3bmFEelNaYkZKWHFHeGo3Ty1JS2FUbjZ6WlRCX3k4QVVUOG9GUFVhV3Jxa05xZl92SXFYY25OdnBoaUxsQjlHWVNWZ01WVnRlZkNPV0ZicDNwU05WT2hjVURRckpERFdlSWxybU9WLVRybWVRQkkwd20tLWcydFBmdmlLX01OclVWY2xNb1ZpR3pMLVlGLU9ocllXcUtFZjczVHljTEFRR3B2dFdR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2024-12-30T08:00:00+00:00", "published_display": "30 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix Inc (CMRX) Quarterly 10-Q Report", "summary": "Chimerix Inc. (CMRX) filed its 10-Q report for the quarter ended September 30, 2024, reporting a net loss of $22.88 million, an improvement from the previous year. Revenue increased to $26,000, primarily due to contract and grant revenue, while R&D expenses rose due to the ACTION", "url": "https://qz.com/chimerix-inc-cmrx-quarterly-10-q-report-1851692369", "source_name": "qz.com", "published_at": "2024-11-07T00:00:00", "published_display": "07 Nov 2024 00:00", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix: Q3 Earnings Snapshot", "summary": "Chimerix Inc. reported a Q3 loss of $24 million, resulting in a loss of 27 cents per share, which missed Wall Street expectations of a 22-cent loss per share. The biopharmaceutical company recorded a revenue of $11,000 for the period.", "url": "https://qz.com/chimerix-q3-earnings-snapshot-1850984379", "source_name": "Quartz", "published_at": "2023-12-31T23:59:59", "published_display": "31 Dec 2023 23:59", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023", "summary": "Chimerix announced it will host a live conference call and audio webcast on Thursday, November 2, 2023, at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2023. The biopharmaceutical company will also provide a business overview during the call.", "url": "https://www.stocktitan.net/news/CMRX/chimerix-to-report-third-quarter-2023-financial-results-and-provide-pqu0w0uwvvv4.html", "source_name": "Stock Titan", "published_at": "2023-10-26T07:00:00", "published_display": "26 Oct 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix (CMRX) Dividend History, Date, and Yield", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVEFVX3lxTE81MHBsR2JZWDAwTng5U1VCUTM0eXRHdnJHNVlvb2xLZlhNWXJhZUxGUlBydk9HbXZPNE9oUVIxeUt6N2ZtVUotWTVhZkxRR1dxVVVjTA?oc=5", "source_name": "CoinCodex", "published_at": "2023-08-09T12:16:10+00:00", "published_display": "09 Aug 2023 12:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix (CMRX) Stock Live Price, Chart & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTFBlMFhhQ2FYUl85ZjBmMFpVWGVuMVVHTHdncjZLdnRWZ2xDWFVzMHBtdlJ4M2lPZlhsMjNRWnFtQVpVbndzd1dhYw?oc=5", "source_name": "CoinCodex", "published_at": "2021-03-20T04:46:14+00:00", "published_display": "20 Mar 2021 04:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimerix (CMRX) Stock Forecast & Price Prediction 2026\u20132030", "summary": "", "url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTE1KTzNrVnVMb3Awc1BVNGk2OExicEJ0UU42cWVXOGluUzVkbDZzRGI3YVl4Q2Rrak0xdVhEVlU2bkN6WTk2eHN6bGF4bUlFMW1CcEtpaGhvU25Ec0Z4Smxn?oc=5", "source_name": "CoinCodex", "published_at": "2021-03-15T10:16:22+00:00", "published_display": "15 Mar 2021 10:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 84, "total_relevant": 44, "sentiment_summary": {"positive": 12, "negative": 5, "neutral": 27, "score": 55, "total": 44, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "deals", "primary_label": "Deals and strategy", "confidence": 72, "events": [{"event": "deals", "label": "Deals and strategy", "weight": 7.7, "count": 14}, {"event": "earnings", "label": "Earnings", "weight": 6.74, "count": 14}, {"event": "general", "label": "Market update", "weight": 6.05, "count": 11}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 8.54, "latest_week": "2026-06-19", "one_week_move": 0.0, "four_week_move": 0.0, "twelve_week_move": 0.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.923291, "market_dynamics_buy_signal": false, "relative_strength": 14.285428, "fair_value_gap": 213.4, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 31.2109, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.0% over one week, +0.0% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 51, "badges": [], "opportunities": [], "risks": [], "event_label": "Deals and strategy", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 5}, {"label": "Stock Titan", "count": 4}, {"label": "CoinCodex", "count": 3}, {"label": "simplywall.st", "count": 2}, {"label": "Meyka", "count": 2}, {"label": "GlobeNewswire", "count": 2}, {"label": "Insider Monkey", "count": 2}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 37}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 14}, {"label": "Deals and strategy", "count": 14}, {"label": "Market update", "count": 11}, {"label": "Regulatory and legal", "count": 2}, {"label": "Macro sensitivity", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Deals and strategy", "tone": "neutral", "text": "72/100 classification confidence."}, {"label": "Company focus", "value": "37", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+0.0% over one week, +0.0% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Glioblastoma Multiforme Market to Witness Transformational Growth Opportunities by 2036 \u2013 DelveInsight | AstraZeneca, DNAtrix, Chimerix, Northwest Therapeutics, Bayer, Kazia Therapeutics, Aivita Bio"}], "updated_at": "2026-06-23T04:48:47.546729+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}